Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Big Japanese Pharmas Plan R&D Push As Patents Expire

This article was originally published in PharmAsia News

Executive Summary

Japan's largest pharmaceuticals are investing heavily in research and development, chasing their next new drug in advance of expiring patent protection on some of their best-sellers that begins next year. Astellas plans a 6 percent increase despite a decreasing profit this year, Daiichi Sankyo and Eisai see R&D increases of 5 percent, each, and Takeda Pharmaceutical, the largest of the four, plans a 6 percent increase in its R&D budget. All but Eisai have major drugs in Phase III testing, while Eisai looks for something in the field of cancer, thanks to its acquisition of MGI Pharma of the United States. (Click here for more - a subscription may be required



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts